Category: 149353-75-3

Synthetic Route of 149353-75-3, In heterogeneous catalysis, the catalyst is in a different phase from the reactants. At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 149353-75-3, name is 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid. In an article，Which mentioned a new discovery about 149353-75-3

The novel RGD mimetics with phthalimidine central fragment were synthesized with the use of 4-piperidine-4-yl-butyric, 4-piperidine-4-yl-benzoic, 4-piperazine-4-yl-benzoic and 1,2,3,4-tetrahydroisoquinoline-7-carboxylic acids as surrogates of Arg motif. The synthesized compounds potently inhibited platelet aggregation in vitro and blocked FITC-Fg binding to alphaIIbbeta3 integrin in a suspension of washed human platelets. The key alphaIIbbeta3 protein-ligand interactions were determined in docking experiments.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.149353-75-3. In my other articles, you can also check out more blogs about 149353-75-3

Reference：
Piperidine – Wikipedia,
Piperidine | C5H23304N – PubChem

 

Chemistry is traditionally divided into organic and inorganic chemistry. Quality Control of: 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent，Which mentioned a new discovery about 149353-75-3

Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Quality Control of: 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid, you can also check out more blogs about149353-75-3

Reference：
Piperidine – Wikipedia,
Piperidine | C5H23315N – PubChem

 

Application of 149353-75-3, In heterogeneous catalysis, the catalyst is in a different phase from the reactants. At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 149353-75-3, name is 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid. In an article£¬Which mentioned a new discovery about 149353-75-3

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QAand drugs containing the same (wherein Q1is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2is a single band, oxygen, sulfur, C1-C6alkylene or the like; QAis optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.149353-75-3. In my other articles, you can also check out more blogs about 149353-75-3

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H23308N – PubChem

 

149353-75-3, 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Production Example 1-8 tert-Butyl 4-(4-((4-((6-methoxy-1-(methylcarbamoyl)-1H-indol-5-yl)oxy)pyridin-2-yl)carbamoyl)phenyl)piperidine-1-carboxylate Benzotriazole (2.32 g, 19.5 mmol) was dissolved in dichloromethane (100 mL), thionyl chloride (1.4 mL, 19.2 mmol) was added under nitrogen atmosphere at room temperature, and the mixture was stirred for 5 minutes. 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid described in Production Example 1-12 (5.4 g, 17.7 mmol) was added to the reaction mixture at mom temperature, and the mixture was stirred for 25 minutes. The reaction mixture was filtered through a glass filter entirely covered with anhydrous sodium sulfate and then washed with dichloromethane, then the filtrate was added to a mixture of 5-((2-aminopyridin-4-yl)oxy)-6-methoxy-N-methyl-1H-indole-1-carboxamide described in Production Example 1-6 (2.5 g, 8.01 mmol), triethylamine (11 mL, 79.4 mmol), and 4-dimethylaminopyridine (101 mg, 0.827 mmol) in tetrahydrofuran (80 mL) at 0 C. The resultant was stirred at mom temperature for 5 hours and then the reaction mixture was concentrated under vacuum. Water and ethyl acetate were added to the residue for partition, and the organic layer was washed with a saturated saline solution, and then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under vacuum, the residue was dissolved in tetrahydrofuran, an excessive quantity of 9.8 M methylamine methanol solution was added at room temperature, and the mixture was stirred for 50 minutes. The reaction mixture was concentrated under vacuum, the residue was dissolved in dichloromethane, and the resultant was purified with NH silica gel column chromatography (n-heptane:ethyl acetate=1:1-1:3-0:1). The target fraction was concentrated under vacuum and the precipitate was collected by filteration and washed with diethyl ether and ethyl acetate to obtain the title compound (3.15 g, 66%). The filtrate was combined with the mixture fraction and the resultant was concentrated under vacuum and dissolved in dichloromethane, and the resultant was purified with NH silica gel column chromatography (n-heptane:ethyl acetate=1:1-1:3-0:1). The target fraction was concentrated under vacuum and the precipitate was collected by filteration and washed with diethyl ether and ethyl acetate to obtain the title compound (264 mg, 5.5%). 1H-NMR Spectrum (CDCl3) delta (ppm): 1.48 (9H, s), 1.55-1.69 (2H, m), 1.77-1.87 (2H, m), 2.64-2.89 (3H, m), 3.02-3.07 (3H, m), 3.86 (3H, s), 4.26 (2H, brs), 5.62 (1H, brs), 6.50-6.55 (1H, m), 6.61 (1H, dd, J=5.9, 2.2 Hz), 7.22 (1H, d, J=3.7 Hz), 7.27-7.33 (3H, m), 7.80 (2H, d, J=8.4 Hz), 7.90 (1H, d, J=2.2 Hz), 8.04 (1H, s), 8.09 (1H, d, J=5.9 Hz), 8.54 (1H, brs)., 149353-75-3

As the paragraph descriping shows that 149353-75-3 is playing an increasingly important role.

Reference£º
Patent; Eisai R&D Management Co., Ltd.; Funasaka, Setsuo; Okada, Toshimi; Tanaka, Keigo; Nagao, Satoshi; Ohashi, Isao; Yamane, Yoshinobu; Nakatani, Yusuke; Karoji, Yuki; US2014/235614; (2014); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem